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Abstract
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine
therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper
describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients
enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-
palbociclib treatment, regardless of the type of therapy received. A small population of long responders were
identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to
palbociclib-based regimens. A translational research program is ongoing on this population of outliers.
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Background
Recent developments in the management of metastatic
breast cancer (mBC) have seen cyclin-dependent kinase
4 and 6 (CDK4/6) inhibitors, given in combination with
endocrine therapy (ET), approved in the USA and in
Europe for the first-line treatment of metastatic hor-
mone receptor-positive (HR+)/human epidermal growth
factor receptor-2 (HER2)-negative disease. Palbociclib
(P), a selective inhibitor of CDK4/6, has shown signifi-
cant activity in the first- or subsequent line treatment of
HR+/HER2-negative mBC when combined with ET,
resulting in an approximate doubling of progression-free
survival (PFS) when compared to ET alone [1–3].
The TREnd trial is a multicenter phase II study that
randomized 115 postmenopausal women with moder-
ately pre-treated HR+/HER2-negative mBC (up to two
lines of prior ET, and/or one line of chemotherapy (CT)
for metastatic disease) to receive P alone, or P in com-
bination with the ET received prior to progression [4].
The rationale of continuing the endocrine agent upon
which disease had previously progressed was based on
preclinical data suggesting palbociclib has the ability to
reverse endocrine resistance [5]. The primary endpoint
of TREnd demonstrated that P has significant clinical ac-
tivity as a single agent. Exploratory analyses suggested
that the combination of P with ET was better than P
monotherapy in terms of duration of clinical benefit
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(11.5 months versus 6 months respectively; HR = 0.35;
95% CI 0.18–0.70, exploratory p value = 0.0021). A simi-
lar trend was also observed in terms of PFS. Further ex-
ploratory subgroup analyses demonstrated that PFS
advantage was observed only in those patients with a
previous durable response to ET (HR, 0.53; 95% CI, 0.3–
0.9, exploratory p value = 0.02), providing the first clin-
ical evidence that P may have potential to reverse ac-
quired resistance to ET.
There is limited data regarding the effectiveness of
standard subsequent line therapies (CT, targeted agents
or ET) after progression on CDK4/6 inhibitor-based reg-
imens, and all analyses thus far have been retrospective
and exploratory in nature. Recent data have emerged
from PALOMA-1 [6] and PALOMA-3 [7], suggesting
that progression on P has no significant effect on the
therapeutic benefit derived from subsequent treatments
received off-trial. In this context, we conducted an ana-
lysis of prospectively collected data from patients
enrolled in TREnd, in order to evaluate the efficacy of
the subsequent line of therapy received after progression
on the assigned trial arm, and the pattern of progression
of disease.
Patients and methods
The study design and baseline characteristics of enrolled
patients on TREnd are described in detail elsewhere [4].
Briefly, at trial entry, three quarters of the overall popu-
lation had pre-existing visceral disease, 69% had received
only one prior line of ET for advanced disease, and 30%
had also received one prior line of palliative CT. Most
patients (73%) had received their most recent pre-trial
line of endocrine therapy for more than 6 months.
The primary endpoint of the current analysis is the
time-to-treatment failure (TTF) of the subsequent line
of therapy received after TREnd, defined as the time
interval between the commencement and discontinu-
ation of next-line therapy for any reason. Additionally,
Fig. 1 CONSORT diagram of evaluated patients
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we identified “long-responder” patients who had a dur-
ation of post-TREnd therapy (ET or CT) falling within
the upper quartile. Clinical benefit (CB) was defined by
the presence of a radiological complete response, partial
response, or stable disease for at least 24 weeks accord-
ing to RECIST 1.1 criteria. Overall survival (OS) was de-
fined as the time from commencement of next-line
therapy to death from any cause.
The cut-off date for the calculation of the TTF was
April 24, 2018. TTF was summarized using the
Kaplan-Meier method. Descriptive statistics were used.
Statistical analyses were performed using R-software.
Results
Of 115 patients enrolled into TREnd, we analyzed 105
patients with available follow-up information collected
between October 2012 and September 2017, with a me-
dian follow-up of 25.8 months, estimated from the first
day of commencing post-TREnd treatment. The median
overall survival (mOS), with 52 events recorded, was
23.9 m (95% CI 18.9–33.8). Figure 1 reports the CON-
SORT diagram of evaluable patients.
After disease progression on TREnd, 9% of patients
had bone-only disease, 76% had visceral involvement,
and 15% had non-visceral disease (nodal +/− bone +/−
skin metastases). Sixty-nine (66%) patients received CT
as next-line treatment, 33 (31%) received ET, and 3 (3%)
received novel or targeted therapies (TT) (Table 1).
The overall median TTF of the next-line therapy was
3.8 months (m) (95% CI 3.5–4.8) and was unaffected by
the arm to which the patient was randomized (Fig. 2a)
(P single agent: mTTF 3.9 m, 95% CI 3.5–6.9 versus P +
ET arm: 3.8 m, 95% CI 2.9–5.1; p = 0.45). Similarly, no
significant differences in TTF were observed according
to whether clinical benefit was attained on TREnd (3.7
m, 95% CI 3.3–5.1 for patients with CB, versus 4.01 m,
95% CI 3.2–7.1, for patients without CB; p = 0.26). Effi-
cacy of post-TREnd therapy was also similar in patients,
Table 1 Type of systemic therapies employed as the immediate subsequent therapeutic line after TREnd (physician choice),
classified by pharmacological classes
Number
Subsequent chemotherapy (n = 69, 66%)
Capecitabine-containing (n = 30) Capecitabine 22
Capecitabine + vinorelbine 6
Capecitabine + vinorelbine + cyclophosphamide 2
Taxane-based (n = 21) Paclitaxel 20
Paclitaxel + BYL79* 1
Anthracycline-based (n = 9) Doxorubicin 1
Epirubicin 1
Doxorubicin + cyclophosphamide 7
Platinum-containing (n = 2) Cisplatin 1
Cisplatin + cyclophosphamide 1
Others (n = 7) Vinorelbine 3
Cyclophosphamide + methotrexate 2
Cyclophosphamide + vinorelbine 2
Subsequent endocrine therapy (n = 33, 31%)
Fulvestrant (n = 20) 20
AIs (n = 7) Letrozole 2
Anastrozole 1
Exemestane 4
AI + mTORi (n = 6) Exemestane + everolimus 5
Exemestane + everolimus + BYL719* 1
Subsequent other targeted/novel therapies (n = 3, 3%)
Lucitanib 1
Ribociclib (single agent) 1
64-Cu-asparagine 1
AIs aromatase inhibitors, mTORi inhibitors of mammalian target of rapamycin
*BYL719 = alpelisib (PI3K inhibitor)
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regardless of the number of ET lines received prior to
trial enrolment (patients treated with one prior line,
TTF 3.8 m, 95% CI 3.4–4.8 versus 3.9 m, 95% CI 3.1–7.4
in patients pre-treated with two prior lines, p = 0.57)
(Fig. 2b). The mTTF according to absolute number of
previous treatment lines received is reported in Table 2,
with comparable findings. There was no significant dif-
ference in mTTF according to whether patients had
received chemotherapy prior to enrolling in TREnd
(3.82 m, 95% CI 3.45–5.72 in patients who were
chemotherapy-naïve versus 3.85 m, 95% CI 2.86–5.07 in
those who received prior chemotherapy; p = 0.15). Simi-
lar mTTF were observed in patients who received ET or
CT post-TREnd (Fig. 2c) (patients who received ET:
mTTF 3.7 months, 95% CI 2.8–4.8 versus patients who
received CT: 4.6 months, 95% CI 3.5–5.8; p = 0.98).
Fig. 2 Kaplan-Meier curves of time to treatment failure (TTF) in the overall population (a). Box plots and comparison of TTF of patients who received
only 1 or ≥ 2 lines of endocrine therapy prior to trial enrolment (b). Box plots and comparison of TTF of patients who received chemotherapy or
endocrine therapy as next-line treatment (c). Abbreviations: P = palbociclib. ET = endocrine therapy. TTF = time to treatment failure. CT = chemotherapy
Table 2 Median time to treatment failure on treatment regimen received immediately after TREnd, according to the absolute
number of previous lines of treatment received. This takes into account previous endocrine therapy line(s) +/− chemotherapy
(TREnd allowed subjects to have a maximum of one previous line of chemotherapy for advanced disease prior to enrolment)
Number of previous lines of treatment received Patients (number) Recorded events (number) Median TTF (months) 95% CI
Two lines 51 47 3.73 3.39–5.07
Three lines 44 43 4.18 3.09–6.28
Four lines 10 9 3.85 2.20–NA
TTF time to treatment failure, CI confidence interval, NA not assessable
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The mTTF of the next-line ET in patients from the P
monotherapy arm was 4.6 m (95% CI 3.7–NA) versus
2.8 m in those previously enrolled in the combination
arm (95% CI 2.8–5.7) (p = 0.36). Similarly, the mTTF of
the next-line CT in patients from the P single-agent arm
was 3.7 m (95% CI 3.3–7) versus 4.8 m (95% CI 3.8–7.4)
in those from the P + ET arm (p = 0.57).
Twenty-five long-responding patients falling within
the upper quartile of TTF on next-line therapy were
identified (cut-off 4.7 m in patients who completed ET
post-TREnd [range 4.7–44], and 7.2 m in those who
completed chemotherapy [range 7.2–36]). Of these, 8
(32%) received ET, and 17 (68%) received CT immedi-
ately following TREnd. The mTTF of these long re-
sponders was 13m (95% CI 12.2 9-NA) in those who
received ET and 10m (95% CI 8.9 10–15) in those who
received CT. Figure 3 reports the characteristics of pa-
tients who received ET immediately following TREnd
and identifies the long-responding patients.
Discussion
CDK4/6 inhibitors have radically changed the manage-
ment of HR+/HER2-negative mBC, with a significant
improvement in median PFS when compared to ET
alone [3, 8–12]. However, questions remain as to
whether CDK4/6 inhibition can improve long-term OS,
and which treatment approach is best to recommend
following progression on CDK4/6 inhibitors. A compara-
tive scarcity of data remains regarding both the effect P
exerts on subsequent therapies such as CT and ET, and
the clinical characteristics of progressive disease after
successive lines.
In this retrospective evaluation of the dataset of
TREnd, the median duration of the treatment received
immediately post-palbociclib did not reach 5 months,
and there were no substantial differences in TTF accord-
ing to the post-palbociclib treatment received. These
findings are similar to those reported in the PALOMA 1
and 3 cohorts [6, 7], suggesting that TTF following pal-
bociclib may be independent of the magnitude of drug
exposure prior to palbociclib. The overall next-line
mTTF of 3.8 m observed in the TREnd dataset is in line
with historical survival data in similar pre-treated study
populations. In women enrolled in the EFECT trial,
which enrolled patients with HR+ mBC progressing on a
non-steroidal aromatase inhibitor to receive either exemes-
tane or fulvestrant, the median time to progression was 3.7
m [13]. Fifty-eight percent of the women in EFECT had re-
ceived at least two prior lines of ET, 23% had received pal-
liative chemotherapy, and 57% had visceral disease
involvement. Similarly, another study demonstrated the
time to disease progression in women receiving capecita-
bine for previously anthracycline-treated, taxane-refractory
mBC was 93 days [14]. In this population, 68% had a pre-
dominantly visceral burden of disease and on average had
received at least two prior palliative chemotherapeutic regi-
mens and one line of ET prior to trial entry. The mOS
noted in the post-TREnd group is also not dissimilar to that
observed in the PALOMA-3 population [7].
In this study, factors including the study arm to which
the patient was allocated, clinical benefit observed on
Fig. 3 Bar plot of post-TREnd TTF in patients who received subsequent ET, scaled on a median value. Abbreviations: TTF = time to treatment
failure. ET = endocrine therapy. AIs = aromatase inhibitors. mTORi =mTOR inhibitors. Values in y-axis are the logarithm of the relationship between
single patient and median duration; 0 represents the median value of TTF. Dotted line: value of 3rd quartile (4.7 months). Gray columns denote
patients who achieved clinical benefit shown on trial; white column: no clinical benefit demonstrated on trial. Hatched-lines column: denotes > 1
previous line of ET received before entering into the TREnd study
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trial, and the agent used as next-line therapy (CT or ET)
following progression on trial had little bearing on the
duration of benefit derived from the next-line therapy.
However, we observed some durable responses to
post-TREnd therapy, albeit in a small number of pa-
tients. To identify and describe the clinical characteris-
tics of these patients, we defined as “long responders”
those who had a TTF in the upper quartile. Interesting
data emerge from the eight long responders who re-
ceived ET as next-line therapy. Of these, 7/8 received
only one single line of ET before enrolment into TREnd,
and 7/8 had received ET for > 6 months prior to
randomization. These analyses, although exploratory and
conducted on a small number of long responders, gener-
ate the hypothesis that a subgroup of patients that ob-
tain CB from a previous ET may not have exhausted the
full potential of ET, even after exposure to P. Therefore,
continuing ET after P could lead to favorable outcomes
in terms of response duration in certain subgroups of
patients. The confounding factor remains our current
inability to prospectively identify such groups. Further-
more, a deeper understanding of the molecular mecha-
nisms of resistance may reveal information to identify
the subgroups that may still derive benefit from continu-
ing ET post-P. Somatic mutations of ESR1 have been
widely implicated in resistance to ET acquired under
drug pressure and are conversely rarely ever identified in
primary, ET-naïve BC [15]. Translational studies of sam-
ples collected in TREnd are ongoing and will include
ctDNA analysis to study the incidence of somatic muta-
tions in a panel of cancer genes including ESR1 and their
correlation with response to ET administered post study.
Patients who demonstrated ongoing endocrine sensitiv-
ity after exiting TREnd may represent an ESR1 wild-type
population. Additional translational studies in the
TREnd cohort include investigation into circulating
markers of prognosis and early response to treatment
and transcriptomic analyses of tumor samples.
In conclusion, our data suggest that subsequent ther-
apies in patients with endocrine resistance who progress
on palbociclib do not generally lead to durable re-
sponses, with the exception of some long responders
who may represent a subgroup with partially preserved
endocrine sensitivity. This highlights the need to develop
new strategies to personalize management within pa-
tients with metastatic luminal disease. Additionally, our
data supports the increasing need to integrate preclin-
ical, translational, and clinical data in order to identify
predictive markers and to develop treatment algorithms
in HR+ HER2-negative mBC.
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